Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer

Basit Öğe Kaydı
dc.authorid0000-0003-0882-0524en_US
dc.authorid0000-0002-7931-2941en_US
dc.contributor.authorİlhan, Yusuf
dc.contributor.authorTatlı, Ali Murat
dc.contributor.authorTeker, Fatih
dc.contributor.authorÖnder, Arif Hakan
dc.contributor.authorKöse, Fatih
dc.contributor.authorGeredeli, Çağlayan
dc.contributor.authorKaplan, Muhammet Ali
dc.contributor.authorOruç, Zeynep
dc.date.accessioned2023-03-13T06:36:32Z
dc.date.available2023-03-13T06:36:32Z
dc.date.issued2022en_US
dc.departmentDicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Medikal Onkoloji Ana Bilim Dalıen_US
dc.description.abstractObjective Cisplatin-paclitaxel and bevacizumab is a frequently used treatment regimen for metastatic or recurrent cervical cancer, and carboplatin-paclitaxel and bevacizumab are also among the recommended regimens. In this study we aimed to evaluate the efficacy of these two regimens for the treatment of metastatic or recurrent cervical cancer. Methods Patients with metastatic or recurrent cervical cancer treated with cisplatin-paclitaxel and bevacizumab or carboplatin-paclitaxel and bevacizumab were retrospectively evaluated in this study. The clinical and demographic characteristics of patients in each group were evaluated. Median overall survival, progression-free survival, and response rates between the two groups were compared. Results A total of 250 patients were included. Overall, the numbers of patients with recurrent disease and metastatic disease were 159 and 91, respectively. The most common histologic subtype was squamous cell carcinoma (83.2%). The median duration of follow-up was 13.6 (range 0.5-86) months. The median progression-free survival was 10.5 (95% CI 9.0 to 11.8) months in the cisplatin-paclitaxel and bevacizumab group (group 1), and 10.8 (95% CI 8.6 to 13.0) months in the carboplatin-paclitaxel and bevacizumab group (group 2) (HR 1.20; 95% CI 0.88 to 1.63; p=0.25). The median overall survival was 19.1 (95% CI 13.0 to 25.1) months in group 1 and 18.3 (95% CI 15.3 to 21.3) months in group 2 (HR 1.28; 95% CI 0.91 to 1.80; p=0.15). Conclusions There is no survival difference between cisplatin or carboplatin combined with paclitaxel and bevacizumab in metastatic or recurrent cervical canceren_US
dc.identifier.citationİlhan, Y., Tatlı, A.M., Teker, F., Önder, A.H., Köse, F., Geredeli, Ç. ve diğerleri. (2022). Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer. International Journal of Gynecological Cancer, 32(4), 502-507.en_US
dc.identifier.doi10.1136/ijgc-2021-003165
dc.identifier.endpage507en_US
dc.identifier.issn1048-891X
dc.identifier.issn1525-1438
dc.identifier.issue4en_US
dc.identifier.pmid35086927
dc.identifier.scopus2-s2.0-85128244977
dc.identifier.scopusqualityQ1
dc.identifier.startpage502en_US
dc.identifier.urihttps://ijgc.bmj.com/content/32/4/502
dc.identifier.urihttps://hdl.handle.net/11468/11368
dc.identifier.volume32en_US
dc.identifier.wosWOS:000748642300001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorKaplan, Muhammet Ali
dc.institutionauthorOruç, Zeynep
dc.language.isoenen_US
dc.publisherBMJ Publishing Groupen_US
dc.relation.ispartofInternational Journal of Gynecological Cancer
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCervical canceren_US
dc.titleCisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical canceren_US
dc.titleCisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer
dc.typeArticleen_US

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu